271 related articles for article (PubMed ID: 26353776)
1. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Cooke NM; Spillane CD; Sheils O; O'Leary J; Kenny D
BMC Cancer; 2015 Sep; 15():627. PubMed ID: 26353776
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
3. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
Schrottmaier WC; Kral JB; Badrnya S; Assinger A
Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
8. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
9. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
10. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.
Egan K; Crowley D; Smyth P; O'Toole S; Spillane C; Martin C; Gallagher M; Canney A; Norris L; Conlon N; McEvoy L; Ffrench B; Stordal B; Keegan H; Finn S; McEneaney V; Laios A; Ducrée J; Dunne E; Smith L; Berndt M; Sheils O; Kenny D; O'Leary J
PLoS One; 2011; 6(10):e26125. PubMed ID: 22022533
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
12. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
14. Progress in platelet blockers: the target is the P2Y12 receptor.
Patel PA; Lane B; Augoustides JG
J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
[TBL] [Abstract][Full Text] [Related]
15. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
Menown IB
Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960
[No Abstract] [Full Text] [Related]
16. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
17. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
20. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]